Download PDF
Horm Metab Res 2015; 47(07): 537-543
DOI: 10.1055/s-0034-1395615
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

The VGF-Derived Neuropeptide TLQP-21 Shows No Impact on Hormone Secretion in the Isolated Perfused Rat Pancreas

C. B. Christiansen
1   Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
,
B. Svendsen
1   Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
,
J. J. Holst
1   Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
› Author Affiliations
Further Information

Publication History

received 16 July 2014

accepted 06 November 2014

Publication Date:
20 January 2015 (online)

Also available at
    Permissions and Reprints

Abstract

TLQP-21 is a VGF-derived neuropeptide proposed to be involved in regulation of metabolism. More specifically it has been suggested that TLQP-21 has the ability to enhance glucose stimulated insulin secretion, making it a candidate for treatment of patients with type 2 diabetes.

In this study, we investigated the impact of TLQP-21 on insulin, glucagon, and somatostatin secretion in the perfused rat pancreas. We found that administration of 5 and 50 nM TLQP-21 had no impact on pancreatic hormone secretion at 3.5 or 8 mM glucose levels. Increasing TLQP-21 (200 nM) and glucose concentration (3.5 and 16 mM) led to a nonsignificant decrease in glucagon secretion, though insulin and somatostatin secretory patterns remained unaffected. In a final set of experiments, perfusions were performed with infusion of 50 and 1 000 nM TLQP-21 to ensure sufficient stimulation. However, administration of TLQP-21 under this setup showed no impact on the pancreatic hormone secretion either. In conclusion, the outcome of this study does not concur with previous findings, suggesting that the effect of TLQP-21 does not directly involve silent hormone secretion.

Key words

type 2 diabetes - insulin secretion - glucagon-like-peptide-1 - glucagon - somatostatin
 

  • References

  • 1 Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52
    CrossrefPubMedGoogle Scholar
  • 2 Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136
    CrossrefPubMedGoogle Scholar
  • 3 Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes?. Trends Endocrinol Metab 2013; 24: 145-152
    CrossrefPubMedGoogle Scholar
  • 4 http://www.who.int/mediacentre/factsheets/fs312/en/
    PubMed
  • 5 Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H, Diamant M. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-2047
    CrossrefPubMedGoogle Scholar
  • 6 Stephens SB, Schisler JC, Hohmeier HE, An J, Sun AY, Pitt GS, Newgard CB. A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet beta-cell survival and function. Cell Metab 2012; 16: 33-43
    CrossrefPubMedGoogle Scholar
  • 7 Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, Torsello A, Bresciani E, Bulgarelli I, Rizzi R, Pavone F, D’Amato FR, Severini C, Mignogna G, Giorgi A, Schininà ME, Elia G, Brancia C, Ferri G-L, Conti R, Cianti B, pascucci T, Dell’Omo G, Mueller EE, Levi A, Moles A. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci USA 2006; 103: 14584-14589
    CrossrefPubMedGoogle Scholar
  • 8 Levi A, Eldridge JD, Paterson BM. Molecular cloning of a gene sequence regulated by nerve growth factor. Science 1985; 229: 393-395
    CrossrefPubMedGoogle Scholar
  • 9 Bartolomucci A, Possenti R, Levi A, Pavone F, Moles A. The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes Nutr 2007; 2: 169-180
    CrossrefPubMedGoogle Scholar
  • 10 Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi AM, Halban PA, Ferri GL, Possenti R, Schinina ME, Levi A. Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 2002; 81: 565-574
    CrossrefPubMedGoogle Scholar
  • 11 Salton SR, Fischberg DJ, Dong KW. Structure of the gene encoding VGF, a nervous system-specific mRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells. Mol Cell Biol 1991; 11: 2335-2349
    PubMedGoogle Scholar
  • 12 Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, Possenti R, Levi A. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 2000; 21: 199-219
    CrossrefPubMedGoogle Scholar
  • 13 Brancia C, Cocco C, D’Amato F, Noli B, Sanna F, Possenti R, Argiolas A, Ferri GL. Selective expression of TLQP-21 and other VGF peptides in gastric neuroendocrine cells and modulation by feeding. J Endocrinol 2010; 207: 329-341
    CrossrefPubMedGoogle Scholar
  • 14 Cocco C, Brancia C, Pirisi I, D’Amato F, Noli B, Possenti R, Ferri GL. VGF metabolic-related gene: distribution of its derived peptides in mammalian pancreatic islets. J Histochem Cytochem 2007; 55: 619-628
    CrossrefPubMedGoogle Scholar
  • 15 Hahm S, Fekete C, Mizuno TM, Windsor J, Yan H, Boozer CN, Lee C, Elmquist JK, Lechan RM, Mobbs CV, Salton SR. VGF is required for obesity induced by diet, gold thioglucose treatment, and agouti and is differentially regulated in pro-opiomelanocortin- and neuropeptide Y-containing arcuate neurons in response to fasting. J Neurosci 2002; 22: 6929-6938
    PubMedGoogle Scholar
  • 16 Jethwa PH, Warner A, Nilaweera KN, Brameld JM, Keyte JW, Carter WG, Bolton N, Bruggraber M, Morgan PJ, Barrett P, Ebling FJ. VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters. Endocrinology 2007; 148: 4044-4055
    CrossrefPubMedGoogle Scholar
  • 17 Rizzi R, Bartolomucci A, Moles A, D'Amato F, Sacerdote P, Levi A, La Corte G, Ciotti MT, Possenti R, Pavone F. The VGF-derived peptide TLQP-21: a new modulatory peptide for inflammatory pain. Neurosci Lett 2008; 441: 129-133
    CrossrefPubMedGoogle Scholar
  • 18 Sibilia V, Pagani F, Bulgarelli I, Mrak E, Broccardo M, Improta G, Severini C, Possenti R, Guidobono F. TLQP-21 a VGF-derived peptide, prevents ethanol-induced gastric lesions: insights into its mode of action. Neuroendocrinology 2010; 92: 189-197
    CrossrefPubMedGoogle Scholar
  • 19 Razzoli M, Bo E, Pascucci T, Pavone F, D’Amato FR, Cero C, Sanghez V, Dadomo H, Palanza P, Parmigiani S, Ceresini G, Puglisi-Allegra S, Porta M, Panzica GC, Moles A, Possenti R, Bartolomucci A. Implication of the VGF-derived peptide TLQP-21 in mouse acute and chronic stress responses. Behav Brain Res 2012; 229: 333-339
    CrossrefPubMedGoogle Scholar
  • 20 Severini C, La Corte G, Improta G, Broccardo M, Agostini S, Petrella C, Sibilia V, Pagani F, Guidobono F, Bulgarelli I, Ferri GL, Brancia C, Rinaldi AM, levi A, Possenti R. In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. Br J Pharmacol 2009; 157: 984-993
    CrossrefPubMedGoogle Scholar
  • 21 Chen YC, Pristera A, Ayub M, Swanwick RS, Karu K, Hamada Y, Rice AS, Okuse K. Identification of a Receptor for Neuropeptide VGF and Its Role in Neuropathic Pain. J Biol Chem 2013; 288: 34638-34646
    CrossrefPubMedGoogle Scholar
  • 22 Hannedouche S, Beck V, Leighton-Davies J, Beibel M, Roma G, Oakeley EJ, Lannoy V, Bernard J, Hamon J, Barbieri S, Preuss I, lasbennes M-C, Sailer AW, Suply T, Seuwen K, Parker CN, Bassilana F. Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. J Biol Chem 2013; 288: 27434-27443
    CrossrefPubMedGoogle Scholar
  • 23 Ali H, Panettieri R. Anaphylatoxin C3a receptors in asthma. Respirat Res 2005; 6: 19
    PubMedGoogle Scholar
  • 24 Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol 2000; 120: 406-412
    CrossrefPubMedGoogle Scholar
  • 25 Possenti R, Muccioli G, Petrocchi P, Cero C, Cabassi A, Vulchanova L, Riedl MS, Manieri M, Frontini A, Giordano A, Cinti S, Gavoni P, Graiani G, Quaini F, Ghé C, Bresciani E, Bulgarelli I, Torsello A, Locatelli V, Sanghez V, Larsen B, Petersen JS, Palanza P, Parmigiani S, Moles A, Levi A, Bartolomucci A. Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J 2012; 441: 511-522
    CrossrefPubMedGoogle Scholar
  • 26 de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443
    CrossrefPubMedGoogle Scholar
  • 27 Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-423
    CrossrefPubMedGoogle Scholar
  • 28 Baldissera FG, Munoz-Perez MA, Holst JJ. Somatostatin 1-28 circulates in human plasma. Regul Pept 1983; 6: 63-69
    CrossrefPubMedGoogle Scholar
  • 29 Fargali S, Garcia AL, Sadahiro M, Jiang C, Janssen WG, Lin WJ, Cogliani V, Elste A, Mortillo S, Cero C, Veitenheimer B, Graiani G, Pasinetri GM, Mahata SK, Osborn JW, Huntley GW, Philips GR, Benson DL, Bartolomucci A, Salton SR. The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure. FASEB J 2014; 28: 2120-2133
    CrossrefPubMedGoogle Scholar
  • 30 Zhang W, Ni C, Sheng J, Hua Y, Ma J, Wang L, Zhao Y, Xing Y. TLQP-21 protects human umbilical vein endothelial cells against high-glucose-induced apoptosis by increasing G6PD expression. PLoS One 2013; 8: e79760
    CrossrefPubMedGoogle Scholar